文献速递类风湿关节炎

类风湿关节炎患者利妥昔单抗维持治疗期间低丙种球蛋白血症的预测因素:一项12年纵向多中心研究

Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
PubMed 文献 · Semin Arthritis Rheum · 2018-02-21

该多中心观察性研究纳入134例接受利妥昔单抗维持治疗至少30个月的类风湿关节炎患者,随访79.5±24.6个月,23例发生低丙种球蛋白血症。基线丙种球蛋白<8g/L是低丙种球蛋白血症的独立预测因素(HR 7.34),合并甲氨蝶呤治疗与风险降低相关(HR 0.26)。

要点

  • 基线丙种球蛋白<8g/L是利妥昔单抗长期治疗中低丙种球蛋白血症的独立预测因素(HR 7.34)。
  • 合并甲氨蝶呤治疗与低丙种球蛋白血症风险降低相关(HR 0.26)。
  • 发生低丙种球蛋白血症的患者严重感染比例更高(26.1% vs 6.3%,P=0.033)。

核心结论

  • 基线丙种球蛋白水平低于8g/L是类风湿关节炎患者长期接受利妥昔单抗治疗后发生低丙种球蛋白血症的强独立危险因素。
  • 合并甲氨蝶呤治疗似乎是长期利妥昔单抗治疗类风湿关节炎患者的保护因素。

研究设计与样本

  • 多中心观察性常规诊疗研究,纳入接受利妥昔单抗维持治疗(最少暴露30个月)的类风湿关节炎患者。
  • 共134例患者符合纳入标准,随访79.5±24.6个月,每次利妥昔单抗输注前进行血清蛋白电泳。
  • 低丙种球蛋白血症定义为总丙种球蛋白<6g/L,严重低丙种球蛋白血症定义为<4g/L。
  • 主要结局为随访期间发生低丙种球蛋白血症。

主要发现

  • 随访期间23例患者发生低丙种球蛋白血症,发生率为每100患者年2.7次事件。
  • 发生低丙种球蛋白血症的平均时间为64±23个月。
  • 发生低丙种球蛋白血症的患者更可能经历严重感染(26.1% vs 6.3%,P=0.033)。
  • 多因素Cox分析显示基线丙种球蛋白<8g/L是低丙种球蛋白血症的独立预测因素(HR 7.34 [95% CI: 2.00-26.90],P=0.003)。
  • 合并甲氨蝶呤治疗也预测低丙种球蛋白血症发生风险降低(HR 0.26 [95% CI: 0.08-0.87],P=0.03)。

关键数值与推荐

  • 低丙种球蛋白血症定义:总丙种球蛋白<6g/L;严重低丙种球蛋白血症定义:总丙种球蛋白<4g/L。
  • 基线丙种球蛋白<8g/L预测低丙种球蛋白血症的HR为7.34(95% CI: 2.00-26.90,P=0.003)。
  • 合并甲氨蝶呤治疗预测低丙种球蛋白血症风险降低的HR为0.26(95% CI: 0.08-0.87,P=0.03)。
  • 发生低丙种球蛋白血症患者严重感染比例为26.1%,未发生者为6.3%(P=0.033)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rituximab (RTX) is an anti-CD20 monoclonal antibody that selectively depletes B-cell population. Thus, it presents a potential risk for the development of hypogammaglobulinemia and related infectious events. Our aim was to identify predictors of hypogammaglobulinemia in RA patients long-term treated with RTX. METHODS: Multicenter observational usual care study of patients with RA on RTX maintenance therapy (minimal exposition of 30 months). Serum protein electrophoresis was performed before each RTX infusion. Hypogammaglobulinemia and severe hypogammaglobulinemia were defined as total gammaglobulin <6g/L and <4g/L, respectively. The primary outcome was the occurrence within the follow-up period of hypogammaglobulinemia. RESULTS: 134 patients met inclusion criteria and were followed-up for 79.5 ± 24.6 months. Hypogammaglobulinemia occurred during the follow-up period in 23 patients (2.7 events per 100 pt-yrs). The mean time to development of hypogammaglobulinemia was 64 ± 23 months. Patients who developed hypogammaglobulinemia were more likely to experience severe infections (26.1% vs. 6.3%, P = 0.033). Multivariate Cox analysis identified gammaglobulin levels <8g/L at baseline as an independent predictor of hypogammaglobulinemia (HR 7.34 [95% CI: 2.00-26.90], P = 0.003). Concomitant methotrexate (MTX) intake was also predictive of a reduced risk of hypogammaglobulinemia occurrence (HR 0.26 [95% CI: 0.08-0.87], P = 0.03). CONCLUSION: Our results show that gammaglobulin levels of less than 8g/L at baseline is a strong independent risk factor for developing subsequent hypogammaglobulinemia, whereas concomitant MTX therapy seems to be a protective factor in RA patients treated long-term with RTX.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Boleto G, Avouac J, Wipff J, et al. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study. Semin Arthritis Rheum. 2018. PMID: 29548542. doi:10.1016/j.semarthrit.2018.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。